ANTROMAX
GREENYN BIOTECHNOLOGY CO., LTD.
ANTROMAX
GREENYN BIOTECHNOLOGY CO., LTD.
Back to Hall of Fame
Antrodia cinnamomea is a unique functional mushroom native to Taiwan, renowned for its multiple health benefits. However, its cultivation was initially limited to rare plants and required at least three years of growth to achieve efficacy, posing significant challenges for broader promotion.
Antromax® Antrodia cinnamomea mycelium is the world's first to be recognized as a New Dietary Ingredient (NDI, NDIN No. 1170) by the U.S. Food and Drug Administration (FDA). Through a patented, eco-friendly cultivation method that does not involve the use of Cinnamomum kanehirae wood, Antromax® employs stress-adapted strain selection. This innovative approach allows for cultivation in just 3–4 months, achieving triterpene levels comparable to a three-year-old fruiting body. It effectively addresses the common issue of low triterpene content in mycelium. This high-efficiency, patented cultivation technology has received multiple international innovation and invention awards.
Backed by years of scientific research and development, Antromax® has undergone studies involving clinical trials, animal models, and cell-based research, continuously validating its diverse benefits. Clinical trials further demonstrate that Antromax® is an effective and safe dietary supplement for health enhancement.
Highlights
- The exclusive solid-state fermentation cultivation uses selected grain-based substrates, eliminating the need for endangered and rare Cinnamomum kanehirae trees.
- Through accelerated cultivation techniques, the triterpene content of Antrodia cinnamomea mycelium is significantly enhanced, achieving levels exceeding those of three-year-old wild Antrodia cinnamomea in just 3–4 months.
- The world’s first Antrodia cinnamomea to receive an unqualified response as a New Dietary Ingredient (NDIN #1170) from the U.S. FDA. Its multiple benefits have also been validated through extensive scientific research.
View Website
Back to Hall of Fame
Antrodia cinnamomea is a unique functional mushroom native to Taiwan, renowned for its multiple health benefits. However, its cultivation was initially limited to rare plants and required at least three years of growth to achieve efficacy, posing significant challenges for broader promotion.
Antromax® Antrodia cinnamomea mycelium is the world's first to be recognized as a New Dietary Ingredient (NDI, NDIN No. 1170) by the U.S. Food and Drug Administration (FDA). Through a patented, eco-friendly cultivation method that does not involve the use of Cinnamomum kanehirae wood, Antromax® employs stress-adapted strain selection. This innovative approach allows for cultivation in just 3–4 months, achieving triterpene levels comparable to a three-year-old fruiting body. It effectively addresses the common issue of low triterpene content in mycelium. This high-efficiency, patented cultivation technology has received multiple international innovation and invention awards.
Backed by years of scientific research and development, Antromax® has undergone studies involving clinical trials, animal models, and cell-based research, continuously validating its diverse benefits. Clinical trials further demonstrate that Antromax® is an effective and safe dietary supplement for health enhancement.
Highlights
- The exclusive solid-state fermentation cultivation uses selected grain-based substrates, eliminating the need for endangered and rare Cinnamomum kanehirae trees.
- Through accelerated cultivation techniques, the triterpene content of Antrodia cinnamomea mycelium is significantly enhanced, achieving levels exceeding those of three-year-old wild Antrodia cinnamomea in just 3–4 months.
- The world’s first Antrodia cinnamomea to receive an unqualified response as a New Dietary Ingredient (NDIN #1170) from the U.S. FDA. Its multiple benefits have also been validated through extensive scientific research.